Fintel reports that on November 5, 2024, William Blair downgraded their outlook for Marqeta (NasdaqGS:MQ) from Outperform to ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

Fintel reports that on October 31, 2024, William Blair downgraded their outlook for Altair Engineering (NasdaqGS:ALTR) from ...

William Blair analysts on Monday raised their revenue and profit estimates for Nvidia over the next two fiscal years, citing ...

William Blair analyst Louie DiPalma has maintained their bearish stance on PLTR stock, giving a Sell rating yesterday. Louie DiPalma has given ...

Glaukos Corporation's Q3 revenue grew 24% to $96.7 million, beating estimates, with an EPS loss of $(0.28). 2024 sales guidance raised despite anticipated headwinds.

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...

On Friday, William Blair issued an upgrade for argenx SE (NASDAQ: ARGX) stock, raising its rating from Market Perform to Outperform. The firm's optimism stems from the success of argenx's Vyvgart ...

ResMed reports Q1 2025 adjusted EPS of $2.20, up 34%, beating estimates. Revenue reached $1.22 billion, up 11%, driven by demand growth.

Fintel reports that on October 30, 2024, William Blair downgraded their outlook for BioMarin Pharmaceutical (WBAG:BMRN) from Outperform to Market Perform. There are 1,150 funds or institutions ...

Altair Engineering (NASDAQ:ALTR – Free Report) had its price target boosted by Royal Bank of Canada from $90.00 to $113.00 in ...